



JFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Mail Stop: PCT**  
Takayuki HIDA et al. : Attorney Docket No. 2006\_1298A  
Serial No. 10/588,542 :  
Filed August 7, 2006 : **THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975**  
SCREENING METHOD

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/\_\_\_\_\_ ; and/or
- each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a.  This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

**and thus no certification and/or fee is required.**

- 1b.  This Information Disclosure Statement is submitted after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1)  the certification of paragraph 2 below is provided, **or**  
(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c.  This Information Disclosure Statement is submitted:  
after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:  
**the certification of paragraph 2 below is provided, and**  
**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified
- a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
  - b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3.  Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
  - a. [X] a full or partial English language translation submitted herewith,
  - b. [] a foreign patent office search report (in the English language) submitted herewith,
  - c. [ ] the concise explanation contained in the specification of the present application at page 2, 3 and 4,
  - d. [X] the concise explanation set forth in the attached English language abstract,
  - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
5. [] A foreign patent office search report citing one or more of the references is enclosed.
6. [] Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Takayuki HIDA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,567  
Attorney for Applicants

WMC/mjw  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
October 13, 2006

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

OCT 13 2006

ATTY DOCKET NO.  
2006\_1298ASERIAL NO.  
10/588,542U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: October 13, 2006

TRADEMARK OFFICE  
APPLICANT  
Takayuki HIDA et al.FILING DATE  
August 7, 2006

GROUP

## FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	AA	01/68862 A1	9/2001	WO			X	
	AB	2002-345468	12/2002	JP			Abstract	
	AC	2004/082598 A2	9/2004	WO			X	
	AD	00/24891	5/2000	WO			Abstract	
	AE	01/48189 A1	7/2001	WO			Abstract	
	AF	02/31111 A2	4/2002	WO			X	
	AG	02/061087 A2	8/2002	WO			X	
	AH	2005/124361 A2	12/2005	WO			X	
	AI	2005/075641 A1	8/2005	WO			Abstract	
	AJ	2005/014616 A2	2/2005	WO			X	

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)


## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		ATTY DOCKET NO. 2006_1298A	SERIAL NO. 10/588,542
		APPLICANT Takayuki HIDA et al.	
Date Submitted to PTO: October 13, 2006		FILING DATE August 7, 2006	GROUP
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AK	M Matsumoto, et al. The novel G-protein coupled receptor SALPR shares sequence similarity with somatostatin and angiotensin receptors. Gene. 248. 183-189. 2000.	
	AL	S Takeda, et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Letters 520 (2002) 97-101.	
	AM	R Bathgate, et al. Human relaxin gene 3 ( <i>H3</i> ) and the equivalent mouse relaxin ( <i>M3</i> ) gene. J. Biol. Chem. 277(2). Pp. 1148-1157. 2002.	
	AN	BMC McGowan, et al. Central relaxin-3 administration causes hyperphagia in male wistar rats. Endocrinology. 146 (8). Pp. 3295-3300. 2005.	
	AO	C Liu, et al. INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J. Biol. Chem. 280 (1). Pp. 292-300. 2005.	
	AP	C Liu, et al. Relaxin-3/Insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR) 135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol. Pharmacol. 67 (1). Pp. 231-240. 2005.	
	AQ	K Boels, HC Schaller. Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor. British Journal of Pharmacology (2003) 140, 932-938.	
	AR	P Sinnayah, et al. Water drinking in rats resulting from intravenous relaxin and its modification by other dispogenic factors. Endocrinology. 140 (11). Pp. 5082-5086. 1999.	
	AS	B Spiegelman, et al. Obesity and the regulation of energy balance. Cell. Vol. 104. Pp. 531-543. 2001.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.